Small molecule inhibitor shows promise in trastuzumab-resistant metastatic breast cancer

Fox Chase Cancer Centre researchers report that a combination of trastuzumab and neratinib (HKI-272) a novel small molecule inhibitor of the HER2 receptor (ErbB2) appears active in women with HER2-positive metastatic breast cancer who have progressed on previous trastuzumab based therapies. More than one-quarter of the women in a phase I/II trial had their tumours shrink on the combination therapy...

Read the whole article on

More from